10x Genomics, Inc. — Form 8-K Summary
Business Context and Reporting Period
10x Genomics filed a current report concerning preliminary second-quarter 2022 revenue for the period ended June 30, 2022, and a change in commercial leadership. The filing references press releases issued July 14, 2022, although the reported earliest event date is July 12, 2022.
Financial Results and Key Metrics
- The company announced preliminary second-quarter 2022 revenue.
- The filing text provided does not include the preliminary revenue amount or comparable prior-period revenue.
- No figures for profit, cash flow, margins, debt, liquidity, or other financial metrics are provided in the filing text.
Material Changes Versus the Prior Comparable Period
The filing does not provide sufficient financial data to assess changes versus the second quarter of 2021 or another comparable period.
Management, Outlook, and Other Items
- James Wilbur, Ph.D., was hired as Chief Commercial Officer effective July 27, 2022.
- Outgoing Chief Commercial Officer Brad Crutchfield is expected to provide transition services through December 31, 2022, unless his employment is terminated earlier.
- The filing does not provide guidance, broader outlook commentary, risk updates, contingencies, or unusual financial items.
- The reported revenue is preliminary and may differ from final reported results.
Investor Verification Items
- Verify the preliminary second-quarter revenue amount in Exhibit 99.1 or the related press release.
- Compare final second-quarter revenue and operating results with the preliminary disclosure.
- Assess the financial and operational impact of the Chief Commercial Officer transition.
- Review subsequent filings for updated guidance, risks, and final financial statements.